Vascular complications and changes in body mass index in Japanese type 2 diabetic patients with abdominal obesity

Background: Although many Asian type 2 diabetic patients have been considered to be not obese and have low capacity of insulin secretion, the proportion of obese patients with visceral fat accumulation has increased in recent years. We found previously considerable number of Japanese non-obese subjects (body mass index (BMI) < 25 kg/m

[1]  Jarett D. Berry,et al.  Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults , 2012, Obesity.

[2]  T. Funahashi,et al.  Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes , 2012, Cardiovascular Diabetology.

[3]  T. Assimes,et al.  Central obesity is important but not essential component of the metabolic syndrome for predicting diabetes mellitus in a hypertensive family-based cohort. Results from the Stanford Asia-pacific program for hypertension and insulin resistance (SAPPHIRe) Taiwan follow-up study , 2012, Cardiovascular Diabetology.

[4]  H. Farzad,et al.  Prognostic significance of the Complex "Visceral Adiposity Index" vs. simple anthropometric measures: Tehran lipid and glucose study , 2012, Cardiovascular Diabetology.

[5]  T. Sanke,et al.  International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values , 2012, Diabetology International.

[6]  T. Funahashi,et al.  Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study) , 2012, Annals of medicine.

[7]  T. Funahashi,et al.  Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes , 2011, Cardiovascular Diabetology.

[8]  T. Funahashi,et al.  Insulin‐secretion capacity in normal glucose tolerance, impaired glucose tolerance, and diabetes in obese and non‐obese Japanese patients , 2011, Journal of diabetes investigation.

[9]  Weiping Jia,et al.  Diabetes in Asia: epidemiology, risk factors, and pathophysiology. , 2009, JAMA.

[10]  T. Funahashi,et al.  Metabolic impact of adipose and hepatic glycerol channels aquaporin 7 and aquaporin 9 , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[11]  岡内 幸義.  Reduction of Visceral Fat Is Associated With Decrease in the Number of Metabolic Risk Factors in Japanese Men , 2008 .

[12]  P Zimmet,et al.  Ethnic comparisons of the cross‐sectional relationships between measures of body size with diabetes and hypertension , 2008, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[13]  D. Tanné,et al.  Effects of Peroxisome Proliferator-Activated Receptor Ligands, Bezafibrate and Fenofibrate, on Adiponectin Level , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[14]  Ho-Young Son,et al.  Epidemic obesity and type 2 diabetes in Asia , 2006, The Lancet.

[15]  S. Kihara,et al.  Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. , 2006, Kidney international.

[16]  M. Kawai,et al.  Increases in body mass index, even within non‐obese levels, raise the risk for Type 2 diabetes mellitus: a follow‐up study in a Japanese population , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[17]  S. Oh,et al.  Cut-off point of BMI and obesity-related comorbidities and mortality in middle-aged Koreans. , 2004, Obesity research.

[18]  S. Kihara,et al.  Adiponectin as a biomarker of the metabolic syndrome. , 2004, Circulation journal : official journal of the Japanese Circulation Society.

[19]  Emile R Mohler,et al.  Peripheral arterial disease: identification and implications. , 2003, Archives of internal medicine.

[20]  M. Matsuda,et al.  Coordinated regulation of fat-specific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9. , 2002, Diabetes.

[21]  S. Kihara,et al.  Adiponectin in essential hypertension. , 2002, Journal of nephrology.

[22]  Jonathan Krakoff,et al.  Adiponectin and development of type 2 diabetes in the Pima Indian population , 2002, The Lancet.

[23]  R. Bergman,et al.  Extreme insulin resistance of the central adipose depot in vivo. , 2002, Diabetes.

[24]  M. Matsuda,et al.  PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.

[25]  G. Lewis,et al.  Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. , 2001, Trends in cardiovascular medicine.

[26]  W. Hiatt,et al.  Medical treatment of peripheral arterial disease and claudication. , 2001, The New England journal of medicine.

[27]  Y. Akanuma,et al.  Risk factors for the development of diabetic retinopathy in Japanese type 2 diabetic patients. , 2001, Diabetes research and clinical practice.

[28]  Bruce M. Spiegelman,et al.  Obesity and the Regulation of Energy Balance , 2001, Cell.

[29]  Stephen J. Aldington,et al.  UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis , 2001, Diabetologia.

[30]  A. Kimmel,et al.  On the Control of Lipolysis in Adipocytes , 1999, Annals of the New York Academy of Sciences.

[31]  A. Bennett,et al.  The assembly of triacylglycerol-rich lipoproteins: an essential role for the microsomal triacylglycerol transfer protein , 1998, British Journal of Nutrition.

[32]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[33]  S. Yamashita,et al.  Enhanced expression of hepatic acyl‐coenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation , 1998, Hepatology.

[34]  W. Fujimoto.  Overview of Non‐insulin‐dependent Diabetes Mellitus (NIDDM) in Different Population Groups , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[35]  S. Yamashita,et al.  Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty , 1996, Nature Medicine.

[36]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[37]  T Nakamura,et al.  Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. , 1994, Atherosclerosis.

[38]  P. Wahl,et al.  Plasma insulin levels in Japanese and Japanese-American men with type 2 diabetes may be related to the occurrence of cardiovascular disease. , 1989, Diabetes research and clinical practice.

[39]  H. Yki-Järvinen,et al.  Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. , 1988, The American journal of medicine.

[40]  P. Björntorp,et al.  Regional differences and effect of weight reduction on human fat cell metabolism , 1979, European journal of clinical investigation.

[41]  T. Funahashi,et al.  The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. , 2011, Journal of atherosclerosis and thrombosis.

[42]  J. Shaw,et al.  Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.

[43]  E. Oda.  New criteria for 'obesity disease' in Japan. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[44]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[45]  C. Conti.  Cardiovascular diabetology. , 1999, Clinical cardiology.

[46]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.

[47]  A. Kissebah,et al.  Relation of body fat distribution to metabolic complications of obesity. , 1982, The Journal of clinical endocrinology and metabolism.